Circumcising men modestly reduces the risk of transmitting
types of human papillomavirus associated with cervical and anal cancer to
women, an analysis of two randomised trials of male circumcision has shown.
The findings, published in The Lancet on January 7, come from two trials conducted in the
Rakai region of Uganda,
in which HIV-negative men were circumcised to test whether it reduced their
risk of HIV infection.
Those studies showed that circumcision reduced the risk of
HIV infection, and as a consequence of these and other studies, the World
Health Organization and UNAIDS now recommend that circumcision of
HIV-negative men should form part of national HIV prevention programmes in
sub-Saharan Africa.
The
studies also showed that circumcision reduced the risk of men acquiring
high-risk forms of human papilloma virus by around 35%, that is, forms of human
papilloma virus associated with the development of cervical cancer in women,
and anal cancer in both sexes.
Circumcision also reduced the risk of genital
ulcer disease, trichomonas vaginalis and bacterial vaginosis in the female
partners of the circumcised men.
Aaron Tobian and Maria Wawer of Johns
Hopkins University,
Baltimore, who
led the Rakai circumcision study with Professor Ron Gray, conducted a further
analysis to determine whether circumcision reduced the risk of acquiring
high-risk types of human papilloma virus for female partners of circumcised men.
The design of
the studies has
been described previously. For the purposes of evaluating the effect of
circumcision on acquisition and clearance of HPV infection in women, HIV-uninfected female partners (648 of men from the
intervention group, and 597 of men in the control group) were simultaneously enrolled
and provided interview information and self-collected vaginal swabs at
baseline, 12 months, and 24 months. Vaginal swabs were then tested for
high-risk HPV.
Female
HPV infection was a secondary endpoint of the trials, assessed as the
prevalence of high-risk HPV infection 24 months after intervention and the
incidence of new infections during the trial.
After
24 months of follow-up, data were available for 544 women in the intervention
group and 488 in the control group, showing that 27.8% of women in the
intervention group and 38.7% of women in the control group had acquired a
high-risk form of human papilloma virus.
The
incidence during the study was 20.7 per 100 person-years of follow-up in the
intervention group, compared to 26.9 infections per 100 person years in the
control group. This represents a 23% reduction in the risk of acquiring
high-risk HPV (incidence rate ratio 0.77, 95% confidence intervals 0.63-0.93,
p=0.008).
The
authors say: "Circumcision of adolescent and adult men in a rural Ugandan
population significantly reduced the prevalence and incidence of both low-risk
and high-risk HPV infections and increased clearance of high-risk HPV
infections in their female partners."
They
conclude: "Along with previous trial results in men, these findings
indicate that male circumcision should now be accepted as an efficacious
intervention for reducing heterosexually acquired high-risk and low-risk HPV
infections in men who do not have HIV and in their female partners. However,
our results indicate that protection is only partial; the promotion of safe sex
practices is also important."
In
a linked Comment, Dr Anna R Giuliano, Department of Cancer Epidemiology and
Genetics, H Lee Moffitt Cancer Center, Tampa,
FL, USA,
and colleagues say: "Recent findings add important evidence for the
promotion of male circumcision in countries without well-established programmes
for cervical screening. Additional interventions to reduce HPV infection, such
as provision of vaccines for HPV prevention, will be essential to reduce
invasive cervical cancer worldwide. Male circumcision is associated with slight
reductions in high-risk HPV, while licensed HPV vaccines protect with high
effectiveness against only a limited number of HPV types. Therefore, the two
interventions are likely to have important synergistic effects."